Introducing Xandr Monetize
5.9.2019 16:00:00 EEST | Business Wire | Press release
Xandr, AT&T’s advanced advertising & analytics company, today announced the launch of Xandr Monetize, a reimagined strategic selling platform built on the powerful foundation of AppNexus technology. Xandr Monetize will enable media companies to unlock the full value of their premium content and improve the advertising experience for consumers.
As content consumption and viewer attention increasingly fragment, Xandr Monetize gives publishers and media owners full control to navigate the consumer journey and client relationships. The platform offers content owners improved monetization, through better inventory management capabilities, data-driven yield optimization, and differentiated buyer demand. With these powerful tools, Xandr Monetize expands the ways in which publishers can package, sell, and measure the performance of their inventory across all screens and devices.
“Xandr is a trusted partner to media companies, attuned to their challenges and innovating in support of their growth. Now, with the size, scale, and resources of AT&T, we are uniquely positioned to offer the scaled, streamlined selling platform the industry needs,” said Ryan Christensen, SVP of Product, Xandr. “With the launch of Xandr Monetize, our future is primed for collaboration that expands and enriches what media companies offer their advertisers and consumers.”
Monetize Together
Xandr Monetize encompasses all the features of the former AppNexus seller products, including an ad server, supply-side platform (SSP), and yield analytics, and now lays the infrastructure for powerful TV capabilities. The platform unifies and simplifies operations across all inventory and transaction types, as well as demand channels. This allows publishers and media owners to focus on creating more content, innovating with advertising formats, and attracting interested consumers.
“The reality for premium publishers in today’s market is that the major platforms are self-interested, yet Xandr’s goals have been consistently aligned with publishers on the open internet. By collaborating closely with us to differentiate our business and innovating to offer buying the way that advertisers want it, Xandr has enabled us to thrive outside of closed ecosystems. Through premium deals and holistic demand channel management, Xandr Monetize sets us up to strategically optimize global revenue,” said Carsten Schwecke, Chairman of the Board, Media Impact, the joint marketing organization of Axel Springer and Funke Mediengruppe.
Xandr Monetize rounds out Xandr’s platform offering of strategic buying and selling solutions. The direct path between Xandr Invest, the strategic buying platform, and Xandr Monetize facilitates scaled buying and unique demand from AT&T, maximizing working media dollars for buyers and direct sellers alike. Xandr Monetize also allows media companies to sell their inventory through Community, Xandr’s curated premium advertising marketplace, to achieve better yield on their premium multiplatform inventory. Buying access to Community is available solely through Xandr Invest.
Monetize for the Future
While building for the future of monetization, Xandr is already tackling the challenges that digital video buyers and sellers face today. The introduction of Programmatic OTT with Prebid brings programmatic demand to TV by enabling competitive separation across multiple SSPs, on Connected TV devices and other digital TV inventory. Xandr’s Programmatic OTT with Prebid offers greater control on par with TV norms, including brand safety and frequency capping, while supporting simultaneous competition for inventory by all programmatic demand. It is available through real-time bidding and deals.
“Developed with our sales needs in mind, Programmatic OTT with Prebid will be essential to better managing inventory within client campaigns and realizing higher yield for our premium content. We have already tested it and are very excited to deploy this capability across the WarnerMedia digital portfolio,” said Amit Chaturvedi, EVP, Head of Revenue Operations & Ad Products, WarnerMedia Ad Sales.
The launch of Xandr Monetize also introduces Prebid Server Premium, Xandr’s simplified server-side header bidding solution, for both SSP and ad server customers. As server-side header bidding opens new channels of header bidding demand and improves site performance, Prebid Server Premium simplifies setup and increases operational efficiency through reporting insights across formats and a single source of clearing across SSPs.
Xandr Monetize offers holistic inventory and demand channel management so media companies can capitalize on the convergence of direct-sold and programmatic campaigns and maximize the value of their inventory. In addition to robust deal capabilities, Xandr now offers Programmatic Guaranteed, allowing publishers to pre-agree with, and execute on, reserved delivery commitments with programmatic buyers without compromising control over how their inventory is monetized.
Foundational to Xandr Monetize are industry-leading forecasting analytics and data-driven yield optimization. Yield analytics, formerly Yieldex, brings a long history of forecasting insights development with unparalleled accuracy. This allows for planning, pacing, and decisioning for direct and programmatic selling throughout the Xandr Monetize product suite, including current and future TV solutions and the ad server.
“Microsoft relies on Xandr as a programmatic advertising partner that can operate at the massive global scale MSN, Outlook, Xbox, and our Windows App Developers require. Over the last ten years of working together, Xandr has been a thoughtful and flexible partner that has helped Microsoft be successful in our rapidly-changing marketplace and with our unique platform needs. The innovation we’ve seen in Xandr Monetize has augmented our programmatic revenue, while simplifying our ad stack. We look forward to continuing our strategic collaboration and pushing the envelope with the future of advertising,” said Kya Sainsbury-Carter, GM of Global Partner Services, Microsoft.
About Xandr
Xandr is AT&T’s advertising company and a leader in addressable TV, creating a better solution for advertisers and media companies. Xandr Invest and Xandr Monetize, our strategic platforms built on more than a decade of AppNexus’ innovation, optimize media spend across screens for buyers and sellers alike. Community, powered by Xandr, is a curated marketplace of premium publishers, providing access to unique consumer insights in a brand-safe environment. For more than 143 years, AT&T has used data and technology to inform and improve the consumer experience.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190905005274/en/
Contact information
Xandr Press Contact
Caroline Smith
914.446.3006
caroline.smith@xandr.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 16:00:00 EEST | Press release
NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under 20 minutes, saving hundreds of hours of engineer time, shrinking MTTR by more than 95%. A global telecommunications firm found NetBrain's context-grounded agents outperformed a stand-alone frontier LLM on a persistent firewall
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 15:00:00 EEST | Press release
Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consistent approach to protecting our innovation and our customers,” said Justin Ferguson, SVP and general counsel at Adtran. “We take all claims seriously, but we will not hesitate to defend ourselves when assertions lack merit. Situations like this place unnecessary strain on technology providers and divert resources from advancing networks and services. By advancing our counterclaim
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 14:00:00 EEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 13:50:00 EEST | Press release
IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio transformation and is expected to strengthen the company’s focus on its innovation-driven businesses: Taste, Scent, and Health & Biosciences. Following the transaction, IFF will be
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 13:00:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 patients, underscoring consistent effectiveness and safety in clinical practice. Additionally, BEQALZI™ (sonrotoclax), which was recently approved by the U.S. Food and Drug Administration, and its development in combination with BRUKINSA (ZS) highlight the potential for next-generation, time-limited treatment approaches in CLL. Amit Agarwal, M.D., Ph.D., Chief Medical Officer, Hematology, BeOne Medicines, said: “CLL is a disease patients live with
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
